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A Bowman-Birk type chymotrypsin 
inhibitor peptide from the 
amphibian, Hylarana erythraea
Luyao Zhang, Xiaoling Chen, Yue Wu, Mei Zhou, Chengbang Ma, Xinping Xi  , Tianbao Chen, 
Brian Walker, Chris Shaw & Lei Wang
The first amphibian skin secretion-derived Bowman-Birk type chymotrypsin inhibitor is described here 
from the Asian green frog, Hylarana erythraea, and was identified by use of molecular cloning and 
tandem mass spectrometric amino acid sequencing. It was named Hylarana erythraea chymotrypsin 
inhibitor (HECI) and in addition to inhibition of chymotrypsin (Ki = 3.92 ± 0.35 μM), the peptide also 
inhibited the 20 S proteasome (Ki = 8.55 ± 1.84  μM). Additionally, an analogue of HECI, named K9-
HECI, in which Phe9 was substituted by Lys9 at the P1 position, was functional as a trypsin inhibitor. 
Both peptides exhibited anti-proliferation activity against the human cancer cell lines, H157, PC-3 
and MCF-7, up to a concentration of 1 mM and possessed a low degree of cytotoxicity on normal cells, 
HMEC-1. However, HECI exhibited higher anti-proliferative potency against H157. The results indicate 
that HECI, inhibiting chymotryptic-like activity of proteasome, could provide new insights in treatment 
of lung cancer.
Serine protease inhibitors are important in many crucial physiological processes within the human body1. Among 
three serine inhibitor families, the Bowman-Birk inhibitors (BBI) found in plants and amphibians, have been 
studied because of their potent protease inhibition. There are two groups of BBIs - one consists of large proteins 
which have more than one reactive site2 and the other consists of short looped peptides normally containing less 
than 20 residues with higher specific activity3.
Most amphibian-derived BBI peptides have been isolated from skin secretions of frogs from the family 
Ranidae, including Lithobates pipiens (pLR), Lithobates sevosus (pYR), Odorrana versabilis (HV-BBI), Odorrana 
hejiangensis (HJTI), Hylarana latouchii (pLR-HL) and Odorrana schmackeri (OSTI)4–9. These BBI peptides con-
tain 17 to 18 amino acid residues, possess a common conserved internal sequence motif -WTKSXPPXP- and 
a single intramolecular disulphide bond which presents the conserved reactive loop10. They possess inhibitory 
activity with Ki values in the micromolar range5–7,9,11. Also, several BBI peptides are also highly potent tryptase 
inhibitors6 and others play important roles in the regulation of immune responses4,12.
Some BBI proteins such as the MSTI from snail medic seeds, BTCI from Black-eyed pea and a trypsin inhibitor 
from Hokkaido large black soybeans have anti-proliferative effects on tumour cells13–15. Several reports suggested 
that the anti-carcinogenic functions of serine protease inhibitors are probably related to their chymotrypsin-like 
and trypsin-like inhibitions on 20 S proteasome15–17. The inhibition of 20 S proteasome may suppress the prolif-
eration of cancer cells through preventing the degradation of pro-apoptotic factors and inhibiting the activation 
of NFκB18.
Here, the discovery of the first chymotrypsin inhibitory BBI peptide from an amphibian skin secretion, is 
described from the Asian green frog, Hylarana erythraea. The peptide was isolated by RP-HPLC fractionation 
by nature of its chymotrypsin inhibitory activity determined by preliminary activity screening. The amino acid 
sequence was determined as TVLRGCWTFSFPPKPCI-amide, by Edman degradation and further confirmed 
by MS/MS fragmentation. An analogue (K9-HECI, TVLRGCWTKSFPPKPCI-amide) which was used for BBI 
inhibitor P1 position analysis, was synthesized in parallel with HECI.
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Results
Identification and structural analysis of HECI. The skin secretion of Hylarana erythraea was fraction-
ated by RP-HPLC over 240 min in the gradient from 0% to 100% buffer B (0.05/19.95/80.0 (v/v/v) TFA/water/ace-
tonitrile) (Fig. 1A). Each fraction was reconstituted in PBS and subjected to the chymotrypsin inhibition assay and 
fraction # 100 was found to exhibit significant chymotrypsin inhibitory activity (Fig. 1B). The MS full-scan analysis 
of this fraction revealed the presence of a single molecule with a molecular mass of 1949.6 Da. Subsequent Edman 
degradation of this peptide found it to be composed of 17 amino acid residues - TVLRGCWTFSFPPKPCI - 
with a C-terminal amidation. MS/MS fragmentation confirmed the sequence as: TVLRGCWTFSFPPKPCI-NH2 
(Table 1), and this novel BBI peptide was named Hylarana erythraea chymotrypsin inhibitor (HECI).
Molecular cloning of the HECI precursor-encoding cDNA from a skin secretion-derived cDNA 
library of Hylarana erythraea. A single transcript encoding the biosynthetic precursor of the novel pep-
tide named, HECI, was repeatedly cloned from the library. From this, both the nucleotide and translated open 
reading frame amino acid sequence of the HECI precursor were successfully determined (Fig. 2A). The bio-
synthetic precursor of HECI consisted of 63 amino acids organized as a putative signal peptide domain of 22 
residues, which was followed by a 21-mer acidic amino acid residue-rich “spacer” peptide. The mature peptide 
sequence followed a typical processing site (-KR-) and ended in a Gly residue, which is a classical amide donor 
for C-terminal amidation. The alignments of the prepropeptides and the cDNAs of amphibian skin-derived BBI 
peptides showed that they exhibited high degrees of similarity. The signal peptide domain and the inhibitory 
motif within the mature peptides, were both highly-conserved (Fig. 2B and C). The loop structure of the HECI 
Figure 1. Identification and structural analysis of HECI. (A) RP-HPLC chromatogram of Hylarana erythraea 
skin secretion. The linear gradient of buffer B (0.05/19.95/80.0 (v/v/v) TFA/water/acetonitrile) is indicated in 
blue line. The arrow indicates the retention time of HECI, about 34% acetonitrile. (B) Chymotrypsin inhibition 
activity screening of HPLC fractions 98–102 min (○ 98 min, ● 99 min, ■ 100 min, □ 101 min, ▲ 102 min).
#1 b(1+) b(2+) Seq. y(1+) y(2+) #2
1 102.055 51.531 T 17
2 201.123 101.065 V 1849.961 925.484 16
3 314.207 157.607 L 1750.892 875.950 15
4 470.309 235.658 R 1637.808 819.408 14
5 527.330 264.169 G 1481.707 741.357 13
6 630.339 315.673 C 1424.685 712.846 12
7 816.419 408.713 W 1321.676 661.342 11
8 917.466 459.237 T 1135.597 568.302 10
9 1064.535 532.771 F 1034.549 517.778 9
10 1151.567 576.287 S 887.481 444.244 8
11 1298.635 649.821 F 800.449 400.728 7
12 1395.688 698.348 P 653.380 327.194 6
13 1492.741 746.874 P 556.328 278.668 5
14 1620.836 810.921 K 459.275 230.141 4
15 1717.888 859.448 P 331.180 166.094 3
16 1820.898 910.952 C 234.127 117.567 2
17 — — I-Amidated 131.118 66.063 1
Table 1. MS/MS fragmentation sequencing data of HECI. Through CID collision, the parent ion was 
fragmented into singly/doubly charged ions. The observed m/z ratios of b-ions y-ions are single-underlined.
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mature peptide possessed the same motif, WTKSXPPXP, as other skin-derived BBI peptides. The distinctive 
structural feature of HECI is that two Phe residues occupy the positions at P1 and P2’ (Fig. 2D)4–7,9,12. The cDNA 
sequence of the HECI precursor has been deposited in the Nucleotide Sequence Database under the accession 
code, MF668238.
Syntheses of HECI and its K9-substituted analogue. HECI and K9-HECI were successfully synthe-
sized with a disulphide bond formed between C6 and C16. Both peptides formed similar secondary structures in 
50% TFE/10 mM ammonium acetate buffer and 10 mM ammonium acetate buffer (Fig. 3A). The percentage of 
each secondary structure type of each peptide in each solvent environment, was calculated and results are shown 
in Fig. 3B.
Trypsin/Chymotrypsin/20 S Proteasome inhibitory activity of HECI and its K9-substituted ana-
logue. HECI exhibited inhibition activity against chymotrypsin with a Ki value of 3.92 ± 0.34 μM (Fig. 4A). It 
also inhibited the chymotrypsin-like activity of the human 20 S proteasome at a similar concentration with a Ki 
of 8.55 ± 1.84 μM (Fig. 4B). K9-HECI showed inhibitory effects against trypsin with a Ki value of 0.79 ± 0.04 μM 
(Fig. 4C). Unexpectedly, the chymotrypsin inhibitory activity of K9-HECI remained. The Ki value was deter-
mined to be 13.88 ± 1.09 μM, which was lower than that of HECI (Fig. 4D).
Cell viability assays of HECI and its K9-substituted analogue on cancer cells, normal cells and 
erythrocytes. Both HECI and K9-HECI were subjected to MTT anti-proliferation assays using PC-3, H157 
and MCF-7 cancer cell lines. Besides HECI was able to inhibit the growth of PC-3 and H157 at 100 μM, both 
peptides inhibited the growth of all cancer cells at 1 mM (Fig. 5A and B). However, both HECI and K9-HECI 
exhibited low degree of inhibition on the normal cell line, HMEC-1 (Fig. 5C). Moreover, both peptides showed 
low degree of haemolytic activity horse erythrocytes (Fig. 5D).
Discussion
In recent decades, short BBI peptides have been found in amphibian skin secretions, which possess potent trypsin 
inhibitory activity. However, to date, there have been no natural amphibian BBI peptides reported with activity 
Figure 2. Molecular cloning of HECI precursor cDNA and sequence alignments. (A) The nucleotide and 
translated open reading frame amino acid sequence of the cDNA encoding the biosynthetic precursor. The 
putative signal peptide is single underlined and the mature peptide is double underlined. (B) The alignment of 
prepropeptides of amphibian BBI peptides. (C) The alignment of prepropeptide encoding cDNAs of amphibian 
BBI peptides. (D) The alignment of amphibian skin-derived BBI mature peptides with the reactive site loop of 
peptides in bold typeface. Identical amino acids and nucleotides are indicated by asterisks.
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against chymotrypsin. Here, we report the first example of a natural chymotrypsin inhibitory BBI peptide, named 
HECI, from the skin secretion of the Asian green frog, Hylarana erythraea.
The signal peptide sequence and cDNA sequence of the biosynthetic precursor of this natural peptide are sim-
ilar to those encoding other BBI peptides from amphibian skin secretions. However, the amino acids at P1 and P2′ 
positions of HECI are both Phe residues, which is consistent with observed chymotrypsin inhibition in this pep-
tide and in other such BBIs19. As expected, HECI showed moderate chymotrypsin inhibitory activity similar to 
that observed for P1 Phe-substituted analogues of amphibian skin-derived trypsin inhibitory BBI peptides5–7,9,11. 
Hence, the peptide analogue K9-HECI was designed and synthesized to determine if trypsin inhibition activity 
could be reverse engineered. Interestingly, K9-HECI was found to have both trypsin and chymotrypsin inhibitory 
activities, therefore we deduced that the P2′ position was also a key position for inhibition specificity of short BBI 
peptides. This hypothesis differs with respect to the function of P2′ sites in large BBI proteins, which are related 
to the peptide hydrolysis rate20.
Several previous reports have shown that chymotrypsin inhibitors generally also have partial inhibitory activi-
ties on the proteasome8. Thus, a proteasome inhibition test on HECI was performed. The result showed that HECI 
had moderate inhibition on the chymotrypsin-like active site of the human 20 S proteasome. Indeed, the highest 
concentration of HECI even showed a more effective inhibition of the 20 S proteasome than it did on chymot-
rypsin. Additionally, the time of HECI inhibition of the 20 S proteasome was longer than that observed for chy-
motrypsin, which might be explained by the higher affinity of HECI for the 20 S proteasome. As we known, 20 S 
proteasome consists of 28 subunits, three of which conduct the tryptic (β2), chymotryptic (β5) and caspase-like 
(β1) activities, respectively21. Whilst, the catalytic nucleophile of proteasome subunits is the highly-conserved 
N-terminal threonine22. Inhibition of proteasome activities and subunit-specific amino-terminal threonine 
Figure 3. Secondary structure analyses of HECI and K9-HECI. (A) The CD spectra of HECI (dot) and K9-
HECI (triangle) were measured in aqueous NH4AC buffer (red colour) and membrane-mimic NH4AC/50%TFE 
buffer (blue colour), respectively. (B) The proportion of different secondary structures domain were predicted 
and calculated using the online software, BeStSel35.
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modification by lactacystin23, differing from the conventional serine in the active site, which may explain the 
different affinity of HECI between chymotrypsin and 20 S proteasome β5 subunit. As the 20 S proteasome plays a 
critical role in regulating many processes in the cell that are important for cancer cell growth and survive, and it 
mainly involves the chymotrypsin-like activity24. We therefore assumed that HECI might have anticancer prop-
erties, which indeed were confirmed in this study.
The major hypothesis of anti-cancer activity of peptides possessing chymotrypsin inhibition is that the peptide 
might be translocated into the cell and react with the related intracellular enzymes like the 20 S proteasome. Also, 
recent research support the idea that the anti-carcinogenic functions of some BBIs might be related to their pro-
teasome inhibition25. Although both peptides inhibited the growth of three cancer cells up to the highest concen-
tration, HECI shows more potent activity against the non-small cell lung cancer, H157 than the others. Indeed, 
proteasome inhibitor has been proved to inhibit a range of cancer cell lines but much more potent against H460, 
another non-small cell lung cancer18, which might be related to the NF-κB-mediated antiapoptotic pathway in 
non-small cell lung cancer26 that decreased the level of Bcl-2 to directly associate with apoptosis27. Interestingly, 
both peptides showed similar degree of inhibition at 1 mM on each cancer cell lines. In this study, we only inves-
tigated the chymotryptic-like activity of proteasome instead of all the catalytic sites, though the K9-HECI might 
be able to inhibit the tryptic-like β5 subunit. Previous study showed that plant-derived BBI, processing the inhib-
itory activity on those three subunits, inhibited the MCF-7 by means of apoptosis15, indicating that inhibition of 
all the subunits could contribute to the apoptosis-induced ability. Obviously, a lower anti-proliferation inhibi-
tory activity of K9-HECI was observed that confirmed the chymotrypsin-like subunit produces the lead effect 
on anti-proliferation of cancer cells15,28,29. That the similar potency of both peptides on MCF-7 but the distinct 
activity on H157 and PC-3 also suggests different apoptosis pathways might be associated with proteasome inhi-
bition. Additionally, considering that membrane transport is required of the peptide, more investigations would 
be needed to assess the transmembrane permeation capabilities of HECI.
Meanwhile, some amphibian skin derived BBIs exhibited antimicrobial activity, which was reported to insert 
into the hydrophobic core of membrane to form transmembrane pores30. The amphipathic peptide can increase 
the membrane permeability that results in the co-delivery of complex molecules from amphibian skin secre-
tion31. It is possible that both peptides could compromise the cell membrane, resulting the inhibition of cell 
proliferation. Additionally, the CD spectra show that HECI has 2-fold greater helix content than K9-HECI in 
a membrane-mimic environment. When the HECI attaches to the cell membrane, it could be more efficient in 
interacting with the cell membrane than K9-HECI due to its higher hydrophobicity as a consequence of the highly 
hydrophobic region (-WTFSFPP-) of HECI32,33. When increasing the concentration to 1 mM, both peptides, los-
ing specificity, showed similar potency against all cancer cells, which could be explained by the non-specific 
membrane permeabilization.
However, both HECI and K9-HECI showed only slight cytotoxicity on HMEC-1 and low degree of haemol-
ysis of mammalian erythrocytes, which suggested that both proteasome inhibition and membrane permeabi-
lization would occur in the antiproliferative activity on cancer cells, but the cell apoptosis through inhibition 
Figure 4. Inhibitory activity of HECI and the Lys-substituted analogue on trypsin, chymotrypsin and the 
20 S proteasome. (A) Progress curves and corresponding Morrison plot for chymotrypsin proteolysis in the 
presence of different concentrations of HECI. (B) Progress curves and corresponding Morrison plot for human 
proteasome 20 S proteolysis in the presence of different concentrations of HECI. (C) Progress curves and 
corresponding Morrison plot for trypsin proteolysis in the presence of different concentrations of K9-HECI. 
(D) Progress curves and corresponding Morrison plot for chymotrypsin proteolysis in the presence of different 
concentrations of K9-HECI. (△ 100 μM, ▽ 75 μM, ● 50 μM, ■ 25 μM, ▲ 10 μM, ▼ 7.5 μM, □ 5 μM, ♦ 
2.5 μM, ◇ 1 μM, ◓ 0.25 μM, ○ 0 μM).
www.nature.com/scientificreports/
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of proteasome might be predominant. Additionally, both peptides exhibited low degree of cytotoxicity on the 
normal cell line, indicating that it might be able to specifically target cancer cells, especially H157. The reason 
behind this is not clear so far, but an explanation of the low cytotoxicity on normal cells is that the expression level 
of proteasome inhibitor could be at a much lower level in normal cells, but higher in cancer cells34.
In summary, this is the first report of a chymotrypsin inhibitory BBI peptide in amphibian skin secretion, 
from the Asian frog, Hylarana erythraea. The peptide possesses inhibitory activities on chymotrypsin and the 
20 S proteasome and its P1 Lys-substituted analogue showed potent trypsin inhibitory activity. HECI also showed 
more potent anticancer activity against PC-3 and H157 cell lines with low degree of cytotoxicity against normal 
cell lines. This study of HECI has provided a new insight into the possible clinical applications of skin-derived BBI 
peptides as well as their roles as potential candidates for natural drug development.
Methods
Acquisition of Hylarana erythraea skin secretion. The skin secretions of four Hylarana erythraea frogs 
were obtained by gentle electrical stimulation and hand massaging, which was described in detail previously 
(Tyler et al., 1992). Briefly, the moist frog dorsal skin was stimulated by 3~5 V, 100 Hz, AC. Then the electrode 
was moved slowly on the skin which was covered by glands for 10 s. Finally, the white secretion was washed off 
by deionized water and immediately snap frozen in liquid nitrogen. The samples were lyophilized for future anal-
ysis. The study was performed according to the guidelines in the UK Animal (Scientific Procedures) Act 1986, 
Figure 5. Effects of HECI and the Lys-substituted analogue on cancer cell lines, a normal cell line and 
erythrocytes. Cell viability of cancer cell line (A) PC-3, (B) H157, (C) MCF-7 and (D) the normal cell line 
HMEC-1 at different concentrations of HECI (dark grey) and K9-HECI (light grey). Statistical significance of 
difference was analysed by two-way ANOVA (*p < 0.05, ****p < 0.0001). (E) Haemolysis rates of HECI and 
K9-HECI on erythrocytes after being incubated for 4 h. The sample for the 0 μM control group was PBS only.
www.nature.com/scientificreports/
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project license PPL 2694, issued by the Department of Health, Social Services and Public Safety, Northern Ireland. 
Procedures had been vetted by the IACUC of Queen’s University Belfast, and approved on 1st March, 2011.
Initially fractionation of skin secretion. Five milligrams of lyophilized skin secretion were dissolved in 
1 ml of deionized water containing 0.05% (v/v) trifluoroacetic acid (TFA, obtained from Sigma-Aldrich, St. Louis, 
MO, USA). The sample was subsequently centrifuged and the supernatant was further filtered through a 0.45 μm 
RC membrane (Phenomenex, Macclesfield, UK). The filtrate was injected into a reverse-phase HPLC system (UV 
Detector: Waters 2489; Binary HPLC Pump: Waters 1525; Autosampler: Waters 2707 (Waters Ireland, Dublin, 
Ireland); Column: Phenomenex Aeris Peptide, C18, 250 × 10.0 mm (Phenomenex, Macclesfield, UK), followed by 
elution with a gradient program from 0.05/99.95 (v/v) TFA/water (0 min) to 0.05/19.95/80.0 (v/v/v) TFA/water/
acetonitrile in 240 min. The column effluent was monitored by UV absorbance at 214 nm, and fractions were 
collected automatically at 1 min intervals.
Chymotrypsin inhibition assay screen. HPLC fractions were dried by Eppendorf Concentrator plus 
(Eppendorf, Hamburg, Germany) in the alcohol/vacuum mode and subsequently reconstituted using 20 μl of 
PBS and each was assayed in duplicate. A volume of 180 μl of substrate working solution containing 50 μM of 
Succinyl-Ala-Ala-Pro-Phe-AMC (Sigma-Aldrich, St. Louis, MO, USA), was added to each well in a black 96-well 
plate. 10 μl of each sample was added into the wells. Then 10 μl of chymotrypsin working solution (1 µg/ml) were 
added to each well. The rate of hydrolysis of the chymotrypsin substrate was monitored subsequently at wave-
lengths of 460 nm emission and 395 nm excitation, at 37 °C, by measuring the rate of increase of fluorescence in a 
FLUOstar OPTIMA multi-well plate reader (BMG Labtech, Ortenberg, Germany).
Identification and structural analysis of HECI. Molecular mass analysis of the contents of the HPLC 
fraction exhibiting maximal chymotrypsin inhibitory activity was achieved by use of an LCQ-Fleet mass spec-
trometer (Thermo Fisher Scientific, San Jose, CA, USA). The major peptide within this fraction was subjected, 
without further purification, to automated Edman degradation using an Applied Biosystems Procise 491 microse-
quencer (Applied Biosystems, Foster City, CA, USA) in liquid phase delivery mode. Finally, the primary structure 
of the novel chymotrypsin inhibitory peptide was confirmed by MS/MS fragmentation sequencing. The detection 
was performed in positive ion mode. The ion capillary tube was heated to 320 °C and the spray voltage was set 
at 4.5 kV. The MS/MS spectrum was analysed using Thermo Scientific Proteome Dicoverer 1.0 software Sequest 
algorithm (Thermo Fisher Scientific, San Jose, CA, USA).
Molecular cloning of HECI precursor-encoding cDNA from the skin secretion cDNA library. A 
further 5 mg of lyophilized secretion was dissolved in lysis/binding buffer of the Dynabeads® mRNA DIRECT™ 
Kit (Dynal Biotech Ltd., Bromborough, UK) which was used to isolate the mRNA from the secretion. The isolated 
mRNA was subjected to 5′- and 3′- rapid amplification of cDNA ends (RACE) procedures to obtain full-length 
peptide precursor nucleic acid sequence data by means of a BD SMART™ RACE cDNA Amplification Kit 
(BD Biosciences Clontech, Palo Alto, CA, USA), and was further subjected to the 3′-RACE procedures using 
a degenerate primer (5′- GGNTGYTGGACNTTYWSNTTY-3′, S = C + G; N = A + C + G + T; Y = T + C; 
W = A + T) that was designed to the internal amino acid sequence, -GCWTFSF-, of HECI. The 3′-RACE PCR 
products were purified (E.Z.N.A.® Cycle Pure Kit) (Omega Bio-Tek Inc., Norcross, GA, USA), and cloned 
using a pGEM®-T Easy Vector (Promega Corporation, Madison WI, USA). The nucleotide sequences of 
cloned cDNAs were obtained by an ABI3730 automated sequencer (Applied Biosystems, Foster City, CA, USA). 
Following the obtaining of the 3′-RACE product sequence, a specific antisense primer was designed to a site 
within the 3′ non-translated region. The 5′-RACE reaction was performed by using this specific antisense primer 
(5′-CCACATCAGATGACTTCCTAATCAT-3′) in conjunction with the UPM RACE primer. Generated PCR 
products were gel purified, cloned, and sequenced as described above.
Synthesis of HECI and the Lys-substituted analogue. The natural HECI (TVLRGCWTFSFPPKPCI-NH2) 
and the Lys-substituted analogue (K9-HECI, TVLRGCWTKSFPPKPCI-NH2) were chemically synthesized using 
a solid-phase peptide synthesis approach to obtain sufficient samples for assaying bioactivities. Briefly, the Fmoc 
protection groups were removed by 20/80 (v/v) Piperidine/dimethylformamide (DMF, obtained from Fisher 
Scientific Ltd, Loughborough, UK) and the peptide bond was coupled in the presence of 2-(1H-benzotriazol-1-yl)-
1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU, obtained from Novabiochem®, Darmstadt, Germany), 
dissolving in 11/89 (v/v) N-methylmorpholine (NMM, obtained from Fisher Scientific Ltd, Loughborough, UK)/
DMF. The process employed Rink amide resin and Fmoc amino acids (Novabiochem®, Darmstadt, Germany), and 
was performed in a Tribute® Peptide Synthesizer (Protein Technologies, Tucson, AZ, USA). The synthesized peptide 
was cleaved from the resin by a reaction containing 2/2/2/94 (v/v/v/v) 1,2-ethanedithiol/H2O/thioanisole/TFA. The 
peptide was washed using diethyl ether and dissolved in 0.05/99.95 (v/v) TFA/water. A final concentration of 0.01% of 
H2O2 was added to perform the formation of the disulphide bond.
Determination of trypsin/chymotrypsin/human proteasome 20 S inhibitory activity of HECI 
and the Lys-substituted analog. Phe-Pro-Arg-AMC, Succinyl-Ala-Ala-Pro-Phe-AMC and 
Suc-Leu-Leu-Val-Tyr-AMC (Abcam, Cambridge, UK) were used as substrates for trypsin, chymotrypsin and 
human 20 S proteasome respectively. 10 μl trypsin/chymotrypsin working solution (1 µg/ml) were added to the 
wells of a micro-titre plate containing 180 μl substrate and various inhibitor solutions. 10 μl human 20 S proteas-
ome (Biochem, Boston, MA, USA) working solution (7 nM) in 50 mM HEPES buffer containing 0.035% SDS, pH 
7.5 was added to the well of a micro-titre plate containing 180 μl substrate solution and each of various inhibitor 
solution. Each determination was carried out in duplicate. The rate of hydrolysis of the trypsin/chymotrypsin sub-
strate was monitored subsequently and continuously, at 37 °C, by measuring the rate of increase of fluorescence in 
www.nature.com/scientificreports/
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a FLUOstar OPTIMA multi-well plate reader (BMG Labtech, Ortenberg, Germany). For the 20 S proteasome, the 
rate of hydrolysis of the substrate was monitored after a pre-incubation for 15 min, at 37 °C. The inhibition curves 
were plotted using Morrison equation, which is showed as follow:
= ×


 +


Q Ki
S
Km
1
(1)
= ×



−
+ + − + + − × ×
×



y V
Et x Q Et x Q Et x
Et
1
( ) ( ) 4
2 (2)
0
2
where, Et is the concentration of enzyme catalytic sites; S is the concentration of substrate; Km is the 
Michaelis-Menten constant; and V0 is the enzyme velocity with no inhibitor. Each assay was repeated three times.
Secondary structure analyses of HECI and the Lys-substituted analogue through circular 
dichroism (CD). The sample peptide solutions (50 μM) were prepared in a 1 mm high precision quartz cell 
(Hellma Analytics, Essex, UK) by 10 mM ammonium acetate and 50% TFE in 10 mM ammonium acetate buffer 
respectively. CD measurements were performed at room temperature by a JASCO J-815 CD spectrometer (Jasco, 
Essex, UK) across the wavelength range from 190 nm-260 nm. The scanning speed was 100 nm/min, the band-
width was 1 nm and the data pitch was 0.5 nm. The CD spectra were further analysed using the online software, 
BeStSel35, and the following proportion of different secondary structures were predicted.
Cell viability test of peptides on cell lines. The cancer cell line H157 (ATCC-CRL-5802, ATCC, 
Teddington, Middlesex, UK) and PC-3 (ATCC-CRL-1435, ATCC, Teddington, Middlesex, UK) were cultured 
in RPMI-1640 culture medium (Invitrogen, Paisley, UK) containing 10% FBS and 1% Penicillin-Streptomycin. 
MCF-7 (ATCC-HTB-22, ATCC, Teddington, Middlesex, UK) was cultured in DMEM culture medium 
(Invitrogen, Paisley, UK) containing 10% FBS and 1% Penicillin-Streptomycin. The normal cell line HMEC-1 
(ATCC-CRL-3243, ATCC, Teddington, Middlesex, UK) was cultured in MCDB131 medium (Gibco, Paisley, 
UK) containing 10% FBS (foetal bovine serum, obtained from Sigma-Aldrich, St. Louis, MO, USA), 1% 
Penicillin-Streptomycin (Invitrogen, Paisley, UK), epidermal growth factor (10 ng/mL), hydrocortisone (1 μg/
mL, obtained from Sigma-Aldrich, St. Louis, MO, USA) and glutamine (10 mM). Cells were seeded into a 96-well 
plate and incubated for 24 h (37 °C, 5% CO2) followed by starvation using serum-free medium. Sample solu-
tions were loaded on this plate which was further incubated for 24 h. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diph
enyltetrazolium bromide (MTT) solution (5 mg/ml, 10 μl/well) was utilized to form the formazan after a 4 h incu-
bation. Cell-produced-formazan was dissolved in DMSO (100 μl/well). The absorbance was recorded by using 
an ELx808TM Absorbance Microplate Reader at 570 nm (BioTek Instruments, Inc., Winooski, VT, USA). All the 
peptide concentrations and controls had 5 replicates in single 96-well plate and three independent experiments 
were performed.
Haemolysis activity test of peptides using horse erythrocytes. Completely washed horse erythro-
cyte (TCS Biosciences Ltd., Buckingham, UK) suspension was prepared using phosphate-buffered saline (PBS). 
A series of peptide solutions were incubated with a 2% suspension of red blood cells at final concentrations of 
1–512 μM at 37 °C for 4 h. After the incubation, 200 μl of each supernatant was transferred into a 96-well plate and 
the absorbance at 550 nm was measured with a Synergy HT plate reader (BioTek Instruments, Inc., Winooski, 
VT, USA). The BioTek’s Gen5TM software was used to analyse the result. (Biolise BioTek EL808, Winooski, VT, 
USA). All the peptide concentrations and controls had 5 replicates in single 96-well plate and three independent 
experiments were performed.
Data availability. All data generated or analysed during this study are included in this published article.
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